Close Menu

More articles about Mass Spec

The collaboration will combine Proteome Sciences' isobaric mass tagging reagents with Thermo Fisher's mass spectrometry systems.

The methods will use AB Sciex's mass spectrometry platforms and aims to develop standardized testing methodologies that may determine the effectiveness and safety of peptide- and protein-based drugs.

Doctors at Geneva University Hospitals will use the company's newly launched SmileMS spectral library search software for LC-MS data to quickly identify toxic compounds in patient samples in the emergency room setting.

LAESI can directly identify proteins, peptides, lipids, and metabolites in biological samples, including tissue, blood, urine, and single cells, Protea said.

The company next year plans to launch a 1,000-patient verification trial for its lung cancer protein biomarker panel, with trials for its Alzheimer's disease panel likely to follow, said an official.

AB Sciex is providing a QTrap 5500 as part of the collaboration

The partnership will focus on developing quantitative, broad-coverage, high-throughput metabolomics for systems biology using AB Sciex's mass spec technology.

Thermo Fisher's sample handling and mass spectrometers will be integrated with IBI's proprietary immunoenrichment technology, and the two firms will develop assays and workflows for the detecting and quantifying low abundance proteins.

Included are a method for analyzing glycoproteins; a method of direct protein identification using MALDI mass spectrometry; and protein biomarkers for cancer sensitivity.

Simultaneous qual-quan workflows generate significantly more data than many conventional mass spec assays, posing a challenge for vendors of ensuring that their software offerings keep pace with the expanded capabilities of their hardware.

"It's taking two workflows and allowing you to do it on one workflow, even in some senses in an a priori manner," a company official said, adding the platform is "the most important launch" in the 26 years he's been with the firm.

ISB researchers will use the company's synthetic peptides and HeavyPeptide AQUA standards in their efforts to develop selected-reaction monitoring and multiple-reaction monitoring mass spectrometry assays for each of the roughly 25,000 human proteins.

New Products: May 28, 2010


ASMS Focus: New Products from Thermo Fisher, Bruker, Waters, Shimadzu, Agilent, and Bio-Rad

Movers & Shakers: May 28, 2010


Sarah Trimpin

1st Base will promote Protoemics International's proteomics services in Singapore, Malaysia, Indonesia, and Thailand.

The company made the disclosures as part of Agilent's fiscal second-quarter earnings report, which showed that total revenues grew 16 percent and that a net loss in the prior-year period swung to a profit in the current quarter.

The collaboration was inspired by the launch last October of Thermo Fisher's Pierce Human In Vitro Protein Expression kits, which MacCoss's lab will use to generate proteins to compile the database.

The researchers developed a hybrid instrument combining elements of a flow cytometer and atomic mass spectrometer, which allows for the quantification of biomarkers in parallel in numbers not achievable with other technologies. They also are aiming to develop a multiplex bead array instrument based on the technology.

The collaboration, which aims to characterize the tryptic peptides of the 5,000 proteins in order to generate mass spectroscopy assays for them, brings together ISB's mass spectroscopy expertise and OriGene's extensive human protein collection.

Participants must be members of ABRF and are expected to serve on PSRG for three years.


The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.